Vulvar and vaginal squamous cell carcinoma · line 1 · Cisplatin radiosensitization (concurrent with EBRT + brachytherapy)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | standard |
| Linked regimen | REG-CISPLATIN-RADIOSENS |
| ID | IND-VULVAR-VAGINAL-SCC-LA-1L-CISPLATIN-RT |
|---|---|
| Type | Indication |
| Status | reviewed 2026-07-11 | pending_clinical_signoff |
| Diseases | DIS-VULVAR-VAGINAL-SCC |
| Sources | SRC-NCCN-CERVICAL-2025 |
Notes
STUB pending clinical co-lead signoff (CHARTER §6.1; dev-mode-exempted per CHARTER §8.3 — draft content only, NOT published/verified clinical advice). PARTIAL — RT dose/field not modellable per KNOWLEDGE_SCHEMA_SPECIFICATION §17, mirrors the IND-CERVICAL-LOCALLY- ADVANCED-CRT pattern exactly. REG-CISPLATIN-RADIOSENS is reused UNCHANGED (no existing file was modified) — its own notes/notes_ua describe cervical FIGO IB3-IVA dosing context, but the weekly- cisplatin component dose (40 mg/m², cap 70mg) is the identical radiosensitizing backbone applied here; RT field/dose for vulvar/vaginal SCC (primary + groin ± pelvic nodes) is planned by radiation oncology, distinct from the cervical pelvic RT + brachytherapy field. No vulvar/vaginal-specific pivotal chemoradiation RCT was found — evidence is extrapolated from cervical (GOG-120) and anal (ACT II) chemoradiation paradigms; flagged as an open evidentiary gap rather than asserting invented response-rate numbers for this specific disease.
Used By
Algorithms
ALGO-VULVAR-VAGINAL-SCC-1L- ALGO-VULVAR-VAGINAL-SCC-1L
Disease
DIS-VULVAR-VAGINAL-SCC- Vulvar and vaginal squamous cell carcinoma
Indication
IND-VULVAR-VAGINAL-SCC-1L-WLE-SLNB- IND-VULVAR-VAGINAL-SCC-1L-WLE-SLNB